Clinical Trial

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.
Protocol Amendment History 46 amendments
This ClinicalTrials.gov record has been amended 46 times since 2015-07-17; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2022-01-24
Status change: Active, Not Recruiting → Recruiting 2020-06-18
Status change: Recruiting → Active, Not Recruiting 2020-04-16
Trial Details
NCT Number NCT02503423
Lead Sponsor Taiho Oncology, Inc.
Conditions Solid Tumors, Lymphoma
Enrollment 253 participants
Start Date 2015-07-14
Primary Completion 2022-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-20